Thousands of bottles of a generic high blood pressure medicine have been recalled because the pills may not dissolve properly and therefore could be ineffective, according to an enforcement report issued by the U.S. Food and Drug Administration (FDA).
The event is listed as a class II recall, which means the medication could “cause temporary or medically reversible adverse health consequences,” and that the likelihood of serious complications is remote.
The recalled drug is a combination prescription tablet containing olmesartan medoxomil, amlodipine, and hydrochlorothiazide. Each of these drugs works in a unique way to lower high blood pressure, which reduces the risk of heart attack and stroke, per Mayo Clinic.
The manufacturer, Macleods Pharma, recalled two lots of the triple-action drug, which were distributed nationwide:
30-count bottles: Lot no. 12251163A (about 3,500 bottles), with the expiration date 05/31/2027
90-count bottles: Lot no. 12251163B (about 200 bottles), with the expiration date 05/31/2027
The name of a drug’s manufacturer and lot numbers can often be found on the printed label of a prescription bottle.
For class II recalls, the FDA says you “can generally continue taking the medicine unless the recalling company provides other instructions.” It may not be safe to stop taking a recalled medication without a replacement.
If you have concerns about your medicine, reach out to your pharmacy or healthcare provider.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Emily Kay Votruba has copy edited and fact-checked for national magazines, websites, and books since 1997, including Self, GQ, Gourmet, Golf Magazine,Outside, Cornell University P...
Monroe Hammond joined Everyday Health in 2021 and now runs the news desk as an editor. They received a master’s degree from the Newmark Graduate School of Journalism at CUNY, as we...
